Mediastinoscopy-assisted Transhiatal Esophagectomy Versus Thoraco-laparoscopic Esophagectomy for Esophageal Cancer
- Conditions
- Esophageal Neoplasms
- Interventions
- Procedure: Thoraco-laparoscopic esophagectomyProcedure: Mediastinoscopy-assisted transhiatal esophagectomy
- Registration Number
- NCT04125849
- Brief Summary
Esophageal cancer is one of the major diseases that seriously threatens an individual's health and life. To reduce the incidence of postoperative complications and mortality of esophageal cancer, thoraco-laparoscopic oesophagectomy (TLE) has been recommended by many guidelines since the 2000s. Additionally, with developments in endoscopy technology in recent years, mediastinoscopy-assisted transhiatal esophagectomy (MATHE) has been used in clinical practice. In 2015, the first mediastinoscopy combined with laparoscopic radical esophagectomy was reported systematically by Hitoshi Fujiwara. This surgical procedure has been performed in many centres in China. However, there is no multicentre prospective randomized controlled study that explored the safety, feasibility and short-term clinical efficacy between mediastinoscopy-assisted transhiatal esophagectomy and thoraco-laparoscopic esophagectomy. We aim to evaluate the feasibility and safety of MATHE.
- Detailed Description
Esophageal resection remains the mainstay of treatment for esophageal cancer patients. Despite improvements in surgical technique and perioperative management, esophagectomy carries considerable operative risk. To reduce the incidence of postoperative complications and mortality of esophageal cancer, the optional of minimally invasive esophagectomy has been recommended by many guidelines since 2000s. In addition, with the development of endoscopy technology in recent years, mediastinoscopy-assisted transhiatal esophagectomy (MATHE) has been used in clinical practices. In 2015, the first mediastinoscopy combined with laparoscopic radical esophagectomy was reported systematically by Hitoshi Fujiwara. This surgical procedure has been performed in many centers of China since then. Compared with MIE, MATHE allows controlled dissection of upper mediastinum and biopsy of mediastinal lymph nodes. No study directly comparing MATHE versus MIE has been reported to date. In this report, we compare MATHE with MIE in terms of surgical feasibility, safety, and survival.We intend to adopt a randomized controlled study method. The study group is mediastinoscopy-assisted transhiatal esophagectomy (MATHE) group, and the control group is thoraco-laparoscopic esophagectomy (TLE) group. This study is expected to provide high-level evidence for the new methods and to provide better treatment options for patients with esophageal cancer.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 160
- 18 years≤age≤ 80 years;
- Histologically diagnosed with squamous cell carcinoma by endoscopic biopsy, cT1-3N0M0;
- Primary tumour is located in the thoracic oesophagus
- No clinical evidence of distant organ metastasis
- No severe comorbidity, can tolerate anesthesia;
- ECOG PS scores≤2;
- The patients sign informed consents by themselves.
- Cervical or abdominal oesophageal carcinoma;
- Previous oesophagectomy, gastrectomy, or mediastinal surgery;
- Current uncontrolled illness such as severe cardiac disease, uncontrollable hypertension or diabetes, or active bacterial infection;
- Unable to tolerate tracheal intubation and general anaesthesia as determined by an anaesthesiologist preoperatively;
- Pregnant or lactating women;
- ECOG PS scores>2;
- Considered unsuitable, such as those who do not agree to participate in the trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Thoraco-laparoscopic esophagectomy Thoraco-laparoscopic esophagectomy Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year. Mediastinoscopy-assisted transhiatal esophagectomy Mediastinoscopy-assisted transhiatal esophagectomy Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
- Primary Outcome Measures
Name Time Method Postoperative respiratory complications 30 days after surgery These respiratory complications involve respiratory distress or failure after the operation with continuation of mechanical ventilation, pulmonary atelectasis requiring sputum suction by bronchoscopy, pneumonia requiring specific antibiotics confirmed by thoracic X-ray or CT scan of the thorax and a positive sputum culture, and acute respiratory distress syndrome.
- Secondary Outcome Measures
Name Time Method Blood loss Intraoperation blood loss during the surgery
postoperative pain score postoperation postoperative pain score
R0 resection rate Intraoperation R0 resection rate
drainage time postoperation drainage time
recurrent laryngeal nerve palsy recurrent laryngeal nerve palsy recurrent laryngeal nerve palsy
pulmonary function indicators 30 days after surgery pulmonary function indicators
anastomotic fistula 30 days after surgery anastomotic fistula
DFS 3 years Disease-free survival,DFS
30-day mortality after surgery postoperation 30-day mortality after surgery
Local recurrence 3 years three-year local tumour recurrence or distant metastasis rate after surgery
postoperative hospital stay postoperation postoperative hospital stay
Lymph node dissection Intraoperation During the surgery, lymph node dissection were performed. The number of removed lymph-nodes were recorded according to the postoperative pathological diagnosis, and the stations of the lymph node were recorded.
duration of surgery Intraoperation Total operation time
Conversion rate Intraoperation conversion to thoracotomy during surgery
Trial Locations
- Locations (1)
Cancer Hospital of Chinese Academy of Medical Sciences Shenzhen Center
🇨🇳Shenzhen, Guangdong, China